New drug target for Alzheimer's identified

Researchers have identified abnormal expression of genes, resulting from DNA relaxation, that can be detected in the brain and blood of Alzheimer's patients.

The protein tau is involved in a number of neurodegenerative disorders, including Alzheimer's disease.

Previous studies have implicated DNA damage as a cause of neuron, or cell, death in Alzheimer's patients.

Given that DNA damage can change the structure of DNA within cells, the researchers led by Bess Frost examined changes in DNA structure in tau-induced neurodegeneration.

They used transgenic flies and mice expressing human tau to show that DNA is more relaxed in tauopathy.

They then identified that the relaxation of tightly wound DNA and resulting abnormal gene expression are central events that cause neurons to die in Alzheimer's disease.

"Our work suggests that drugs that modify DNA structure may be beneficial for treating Alzheimer's Disease," they wrote.

The study is published in the journal Nature Neuroscience.